Effect of neoadjuvant chemotherapy in combined with laparoscopy on the molecular markers and immune function in patients with locally advanced cervical cancer

Objective: To explore the efficacy of paclitaxel plus cisplatin (TP) neoadjuvant chemotherapy in combined with laparoscopy in the treatment of locally advanced cervical cancer and their effect on the molecular markers and immune function. Methods: A total of 92 patients with locally advanced cervical cancer were included in the study and divided into the control group (n=46) and the treatment group (n=46) according to the admission number. The patients in the control group were given 5- fluorouracil plus cisplatin (PF), neoadjuvant chemotherapy in combined with laparoscopic radical hysterectomy. The patients in the treatment group were given TP neoadjuvant chemotherapy in combined with laparoscopic radical hysterectomy. The clinical efficacy in the two groups was compared. The levels of molecular markers and the change of immune function in the two groups were detected and compared. The adverse reactions in the two groups were observed and compared. Results: After chemotherapy, in the treatment group, CR was 39.13%, PR was 41.30%, NC was 13.04%, PD was 6.52%, and the total effective rate was 80.43%, while those in the control group were 21.74%, 26.09%, 30.43%, 21.74%, and 47.83%, respectively. The total effective rate in the treatment group was significantly higher than that in the control group. The comparison of the occurrence rate of adverse reactions between the two groups was not statistically significant. CEA, SCC-Ag, CYFRA21-1, and CA125 levels 2 weeks after operation in the two groups were significantly reduced when compared with before treatment, and those in the treatment group were significantly lower than those in the control group. MMP-2, TIMP-2, VEGF-C, and VEGF-D levels 2 weeks after operation in the two groups were significantly reduced when compared with before treatment, and those in the treatment group were significantly lower than those in the control group. CD 3 + , CD 4 + , and CD 8 + 2 weeks after operation in the two groups were significantly reduced when compared with before treatment, while CD 4 + /CD 8 + was significantly elevated, but the comparison between the two groups was not statistically significant. Conclusions: Given TP neoadjuvant chemotherapy in combined with laparoscopy in patients with locally advanced cervical cancer can obviously enhance the patient's clinical efficacy, reduce the molecular markers in the body, effectively improve the patient's immune functionwith less adverse reactions and accurate efficacy; therefore, they are safe and reliable